Radiopharmaceutical Theranostics Market (Product Type, Radioisotope) - Reach $3.44Bn by 2028 at 11.3% CAGR with Cyclotrons Segment Driving Growth During 2022–2028 | The Insight Partners

The Insight Partners published latest research report on "Radiopharmaceutical Theranostics Market Trends Report, Growth, Share, Size & Forecast to 2028 - COVID-19 Impact and Global Analysis By Product Type, Radioisotope, Source, Indication and End User”, the global market size is expected to grow from USD 1,814.58 million in 2022 to USD 3,441.97 million by 2028; it is estimated to record a CAGR of 11.3% from 2022 to 2028.

Request Sample PDF Brochure: https://www.theinsightpartners.com/sample/TIPRE00024328

Product Developments by the Key Players Operating in the Global Radiopharmaceutical Theranostics Market:

Mar-23: GE HealthCare announced, at the European Congress of Radiology (ECR) in Vienna, Austria, the completion of Phase I subject recruitment in its early clinical development program for a first-of-its-kind manganese-based macrocyclic magnetic resonance imaging (MRI) contrast agent. Typically, MRI agents – used to enhance visualization of abnormal structures or lesions and to aid differentiation between healthy and pathological tissue – are gadolinium-based. This manganese-based agent could broaden GE HealthCare’s portfolio of MRI contrast agents available to radiologists, providing a potential alternative in light of perceived concerns about gadolinium retention.

Nov-22: GE Healthcare’s DaTscan had been approved by the U.S. Food and Drug Administration (FDA) for use in patients with suspected Dementia with Lewy Bodies (DLB).  This new indication is in addition to using single photon emission computed tomography (SPECT) imaging to visualize dopamine transporters (DaT) in the brains of adult patients with suspected Parkinsonian syndromes.  With the expanded indication, DaTscan has been made available to more patients in the United States, including those with suspected DLB.

Nov-22: Curium had announced that it intended to submit updated labeling to the U.S. Food and Drug Administration (FDA) for its generic DaTscan (Ioflupane I 123 Injection) version) to include a new indication and updated safety information.  The additional indication assists in evaluating adult patients for striatal dopamine transporter visualization using single photon emission computed tomography (SPECT) brain imaging with suspected dementia with Lewy bodies (DLB).

Nov-22: Telix announced that Illuccix (Ga 68 gozetotide injection) with up to 50mCi for radiolabeling was available for use on 100mCi (millicurie) gallium generators, an important development in radioisotope production. This technology increases the number of daily elutions and activity in each elution, enabling hospitals and radiopharmacies to increase the number of daily doses produced, expand their service area, and gain greater production efficiency.

Oct-22: Telix announced that Health Canada had approved Illuccix [kit for the preparation of gallium (68Ga) gozetotide injection] for use in staging and re-staging intermediate and high-risk prostate cancer and localizing tumor tissue in recurrent prostate cancer. Illuccix was Canada's first PSMA PET imaging agent to be granted regulatory approval. Health Canada was the third regulatory body worldwide to approve Illuccix, which is commercially available in Australia and the United States.

Oct-22: NuView Life Sciences, Inc is a clinical-stage precision oncology company focusing on innovative approaches, such as theranostics, to diagnose and treat cancer. NuView is leveraging its clinical-stage small molecule, NV-VPAC1, to advance its unique theranostic technology for precision diagnostics and targeted therapy. NV-VPAC1 binds directly to VPAC1 receptors found in high densities in breast cancer tumors. With FDA approval being sought for NV-VPAC1, there is the potential to attain tremendous benefit. Prospective advantages include the ability to differentiate malignant from benign breast lesions regardless of the level of density (BI-RADS) and the ability to improve the quality of life in patients while they are being diagnosed.

Directly Purchase Premium Copy of Radiopharmaceutical Theranostics Market Growth Report (2022-2028) at: https://www.theinsightpartners.com/buy/TIPRE00024328

Jun-22: Lantheus presented study results providing independent validation of PYLARIFY AI, the Company’s artificial intelligence (AI) platform developed to assist in standardized PSMA PET/CT scan quantification. PYLARIFY AI is an FDA-cleared medical device software commercially available in the United States. The results were presented at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) annual meeting and demonstrated the higher efficiency and consistency of the PYLARIFY AI platform while maintaining the diagnostic accuracy of PSMA imaging in prostate cancer.

May-22: Lantheus announced the first patient had been dosed in a Phase 2 trial evaluating NM-01, its proprietary technetium 99m SPECT imaging agent used to assess PD-L1 expression in Non-Small Cell Lung Cancer (NSCLC) cells and for its potential to identify patients who would respond to checkpoint inhibitor therapies.

Apr-22: Curium announced that the U.S. Food and Drug Administration (FDA) approved its generic version of DaTscan (Ioflupane I 123 Injection) on March 30, 2022. Ioflupane I 123 Injection is a single-photon emission computed tomography (SPECT) brain imaging agent used to evaluate adult patients with suspected Parkinsonian Syndromes. However, the company began accepting customer orders for fulfillment beginning in April.

Mar-22: Novartis announced that the US Food and Drug Administration (FDA) had approved PluvictoTM (lutetium Lu 177 vipivotide tetraxetan) (formerly referred to as 177Lu-PSMA-617) for the treatment of adult patients with a certain type of advanced cancer called prostate-specific membrane antigen–positive metastatic castration-resistant prostate cancer (PSMA-positive mCRPC) that has spread to other parts of the body (metastatic).

Global Radiopharmaceutical Theranostics Market Share Report, Segmentations, Regional & Country Scope:

Browse key market insights spread across 185 pages with 165 list of tables & 90 list of figures from the report, "Radiopharmaceutical Theranostics Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Product Type [Alpha Emitters, Beta Emitters, and Positron Emission Tomography (PET) Tracers], Radioisotope [Technetium-99, Gallium-68, Iodine-131, Iodine-123, 18F, Y-90, Lutetium (Lu) 177, Copper (Cu) 67, Copper (Cu) 64, and Others], Source (Nuclear Reactors and Cyclotrons), Application [Targeted Therapeutic (Rx) and Companion Diagnostic (DX)], Indication (Oncology, Cardiology, Neurology, and Others), and End User (Hospitals, Diagnostic Imaging Centers, Academic and Research Institutes, and Others)" in detail along with the table of contents: https://www.theinsightpartners.com/reports/radiopharmaceutical-theranostics-market

Feb-22: Theragnostics announced that NephroScan, its radiodiagnostic imaging drug used to evaluate renal parenchymal disorders in adult and pediatric patients, including term neonates, has received Marketing Approval from the US Food and Drug Administration (“FDA”).  GE Healthcare to commence distribution in the US and is manufactured by ROTOP Pharmaka in Germany

Dec-21: Telix was pleased to announce that the U.S. Food and Drug Administration (FDA) had approved Illuccix (TLX591-CDx), Telix’s lead prostate cancer imaging product. Illuccix is a kit for the preparation of gallium-68 (68Ga) gozetotide (also known as PSMA-11) injection, a radioactive diagnostic agent indicated for positron emission tomography (PET) of prostate-specific membrane antigen (PSMA) positive lesions in patients with prostate cancer.

Nov-21: Lantheus announced that PYLARIFY AI, an FDA-cleared medical device software, was commercially available in the United States. PYLARIFY AI employs a deep learning algorithm that has been trained and validated across more than 3,000 images to allow healthcare professionals and researchers to perform standardized quantitative assessments of PSMA PET/CT images in prostate cancer.

Oct-21: Curium announced that the Company had received a Study May Proceed letter from the U.S. Food and Drug Administration (FDA) to begin its Phase 3 trial with its investigational product lutetium Lu 177 PSMA I&T, a therapeutic radiopharmaceutical that binds to the Prostate-Specific Membrane Antigen (PSMA) protein.

Sep-21: Novartis announced that the US Food and Drug Administration (FDA) had accepted and granted Priority Review to the company’s New Drug Application (NDA) for 177Lu-PSMA-617, an investigational targeted radioligand therapy for metastatic castration-resistant prostate cancer (mCRPC) in the post-androgen receptor pathway inhibition, post-taxane-based chemotherapy setting.

May-21: Lantheus announced that the U.S. Food and Drug Administration (FDA) had approved PYLARIFY, an F 18-labeled prostate-specific membrane antigen (PSMA) targeted positron emission tomography (PET) imaging agent to identify suspected metastasis or recurrence of prostate cancer. PYLARIFY was the first and only commercially available approved PSMA PET imaging agent for prostate cancer.

Mar-21: Novartis reported that the first interpretable results of the Phase III VISION study evaluating the efficacy and safety of 177Lu-PSMA-617, a targeted radioligand therapy in patients with progressive PSMA-positive metastatic castration-resistant prostate cancer (mCRPC), compared to the best standard of care alone. The trial met both primary endpoints of overall survival and radiographic progression-free survival, helping to move closer to the ambition of becoming the targeted treatment for >80% of patients with advanced prostate cancer.

Inquire before Buying: https://www.theinsightpartners.com/inquiry/TIPRE00024328/

Nov-20: NuView Life Sciences developed a unique and proprietary binary test to diagnose cancer more accurately by targeting only cancer cells. As a first-of-its-kind technology, NuView Life Sciences combined their proprietary NV-VPAC1 peptide construct with the radionucleotide Copper-64 [(64)Cu] for diagnostics and Cu for treatment. Research shows that malignant cells accumulate (64)Cu in much greater quantities than normal, healthy cells. As a result, the NV-VPAC1 peptide construct targets cancer cells, binding to specific receptors, called VPAC1 receptors, which are overexpressed on the surface of cancer cells. NV-VPAC1 also identifies cancerous cells shed from the body in biofluids like urine, thus offering diagnosis without radiation.

Jan-20: Jubilant Radiopharma, a business unit of Jubilant Pharma Limited, announced today that they received approval from Health Canada for Drax Exametazime (Kit for the Preparation of Tc99m Exametazime for leukocyte labeling).  Leukocyte labeling scintigraphy is a nuclear medicine imaging procedure that helps physicians localize the intra-abdominal infection and inflammatory bowel disease.

Radiopharmaceuticals are important in the diagnosis and therapy of cancer. A diagnostic scan with 123I, 124I, or low-activity 131I-iodide is followed by therapy with high-activity 131I-iodide. Similarly, adrenergic tumors such as pheochromocytoma and neuroblastoma can be imaged with 123 I-Metaiodobenzylguanidine and treated with 131 I-Metaiodobenzylguanidine. Bone scintigraphy can be used to select patients with painful bone metastases from prostate cancer who might benefit from treatment with beta or alpha-particle-emitting bone-seeking agents, the newest and most successful of which is 223Ra radium chloride. More recently established theranostics include somatostatin receptor targeting peptides for diagnosing and treating neuroendocrine tumors with agents such as 68Ga-DOTATATE and 177Lu-DOTATATE, respectively. We have built on the radioiodine experience with recently licensing somatostatin peptides, and the rapid introduction of 68Ga and 177Lu labeled prostate-specific membrane antigen targeting agents. There is also a large expansion in the availability of widely accepted theranostic radiopharmaceuticals.

Impact of COVID-19 Pandemic on Global Radiopharmaceutical Theranostics Market Growth:

The COVID-19 pandemic has significantly impacted the radiopharmaceutical theranostics market. During the pandemic, most companies experienced disruptions in supply chains owing to transport restrictions. The crisis also resulted in supply issues associated with radiopharmaceuticals, radioisotopes, and therapeutic and diagnostic kits. Nuclear medicine and personalized medicine rely heavily on the timely availability of radioisotopes. Air freight restrictions hampered the transport of Molybdenum-99, Technetium-99m, and other radioisotopes.

As per the Society of Nuclear Medicine and Molecular Imaging (SNMMI), ~80% of survey respondents saw 50–75% decline in non-PET nuclear medicine procedures. In addition, the COVID-19 crisis and its adverse effects on the regular operations of radiopharmacy labs led to changes in policies for radiopharmaceutical preparations in nuclear medicine (NM) departments. In many radio pharmacy labs, diagnostic imaging tests were quantitatively reduced, and test procedures dropped down to almost half (18%) in imaging centers.

Appointments for cancer diagnosis and surgeries were either postponed or cancelled due to the unavailability of medical staff and resources in 2020. For instance, in 2020, Breastcancer.org surveyed 534 patients in the US, revealing that ~31.7% of people diagnosed with breast cancer reported a delay in care; of these people, 22% reported delayed screening and 9.3% reported a delay in treatments. As a result, the pandemic had a negative impact on the market.

Speak To Analyst: https://www.theinsightpartners.com/speak-to-analyst/TIPRE00024328

However, in the post-pandemic period, more cases of advanced cancers are expected in coming years due to delayed diagnosis and postponed medical appointments. The huge unmet needs and the ensuing massive opportunity for imaging technologies and services will benefit the long-term growth of radiopharmaceuticals. Growth during this period will continue to benefit from the growing mainstream interest in nuclear medicine and the development of new radionuclides for cancer nuclear imaging and internal radiotherapy, supporting the growth of the radiopharmaceutical theranostics market.

Based on indication, the global radiopharmaceutical theranostics market is segmented into oncology, neurology, cardiology, and others. In 2022, the oncology segment held the largest share of the market, and it is expected to register the fastest CAGR during the forecast period. Theranostics methods involve administering nanoparticles into the patient’s body. These methods can be applied in the treatment of esophageal cancer, prostate cancer, breast cancer, and others. Several radiopharmaceuticals are routinely used in clinical practice, such as [68Ga/177Lu] DOTATATE, and dozens are under preclinical development. [18F] FDG has been widely in use in treating cancer and brain disorders. In March 2022, Novartis received the US FDA approval for Pluvicto (lutetium Lu-177 vipivotide tetraxetan) (formerly referred to as 177Lu-PSMA-617) for treating adult patients with prostate-specific membrane antigen–positive metastatic castration-resistant prostate cancer (PSMA-positive mCRPC). It is the first FDA-approved targeted radioligand therapy (RLT) that combines a targeting compound (ligand) with a therapeutic radioisotope (a radioactive particle). Thus, the strong clinical need for these therapies and targeted treatments in oncology continues to fuel the search for new theranostics treatment opportunities. Therefore, such factors are expected to boost the radiopharmaceutical theranostics market for the segment in the forecast period.

Cancer is one of the leading causes of death worldwide, responsible for almost 10 million deaths in 2020, or almost one in six. The most common types of cancer are breast, lung, colon, rectum, and prostate. According to National Cancer Registry Program Report 2020, in India, male cancer cases were estimated at 679,421 in 2020 and are expected to further increase to about 763,575 in 2025, while female cancer cases were estimated at 712,758 in 2020 and 806,218 in 2025. As people age, they become immunocompromised and often succumb to cancer risks. Poor lifestyles, longer working hours, increasingly stressful lives, smoking, alcohol consumption, contraceptive use, nulliparity, and reduced breastfeeding all contribute to breast cancer incidence.

According to the American Cancer Society’s 2023 report, ~43,720 new cases of thyroid cancer (12,540 in men and 31,180 in women) are recorded in 2023. The report also revealed that 2,120 deaths occurred from thyroid cancer (970 in men and 1,150 in women) in the same year. Radiopharmaceutical theranostics have promising potential in cancer therapy. Theranostics is the combination of therapeutic and diagnostic techniques that utilize a suitable radiopharmaceutical agent. For example, radioiodine has a well-known theranostic application in diagnosing and treating differentiated thyroid cancer. Several radiopharmaceutical theranostic pairs are available for breast cancer applications. These pairs include 43/44Sc/47Sc, 64Cu/67Cu, 83Sr/89Sr, 86Y/90Y, 110In/111In, 124I/131I, 152Tb/161Tb, 152Tb/149Tb, 68Ga/177Lu, and 90Y/177Lu. 123I/131I is a well-known example of theranostic pair that is used in high-quality single-photon emission computerized tomography (SPECT)/CT for pre- and post-therapeutic assessment of thyroid cancer.

Go through further research published by The Insight Partners: (Purchase with 10% Instant Discount):

Radiopharmaceuticals Market Forecast to 2028 - COVID-19 Impact and Global Analysis

Radiotherapy Market Forecast to 2028 - COVID-19 Impact and Global Analysis

Image Guided Radiotherapy Market Forecast to 2028 - Covid-19 Impact and Global Analysis

Radiotherapy Devices Market Forecast to 2028 - Covid-19 Impact and Global Analysis

About Us:

The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Chemicals and Materials.

Contact Us:

If you have any queries about this report or if you would like further information, please contact us:

Contact Person: Sameer Joshi

E-mail: sales@theinsightpartners.com 

Phone: +1-646-491-9876

Press Release: https://www.theinsightpartners.com/pr/radiopharmaceutical-theranostics-market